Ready to donate?

You are able to book 3 or more days in advance.

Request appointment now

or

To change an existing appointment, or to speak to a customer service representative

13 14 95

2015/16 Collaborators

Institution Research area and Project Collaborator(s)
Universities    
Australian National University Product safety: Cellular processes that regulate the lifespan of red blood cells. Prof. Simon Foote, Dr Brendan McMorran, Dr Gaétan Burgio
Deakin University Donor Behaviour: Evaluating a model for culturally relevant interventions to increase blood donation and overcome perceived blood donation barriers among migrant communities. Prof Michael Polonsky, Prof. Andre Renzaho, Prof. Sandra Jones
James Cook University Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.): disease burden and consequences for blood supply safety. Prof. John McBride
Monash University Product usage: Transfusion Outcomes Research Collabrative (TORC). Prof. J Mc Neill and members of the TORC Steering committee
Queensland University of Technology Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? Prof. Louise Hafner
  Product safety: reducing the risk of TRALI Prof. Adrian Barnett, Anne-Marie Christensen
  Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate. Prof. Rebekah Russell-Bennett
  Product safety: Points of structural failure that may lead to storage-related changes of red cells. Prof. YT Gu, Dr E Sauret, Dr S Saha and Prof. Y Xiao, Sarah Barns
  Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative? Christine Knauth
  Product safety: Is parvovirus B19 a concern for the blood safety in Australia? Dr Francesca Frentiu
University of Newcastle Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? Prof. Stephen Graves
University of NSW Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? Dr Heather Gidding
  Donor behaviour: The role of pride in motivating and maintaining blood donations.
Donor behaviour: Emotional Psychology of Blood Donors.
Dr Lisa Williams
  Product develoment and storage: Biomimetic blood bag materials for prolonged platelet storage. Prof. John Whitelock, Dr Megan Lord, Dr Brooke Farrugia
University of Queensland Product safety: Reducing the risk of TRALI. Prof. Michael Reade
  Donor Behaviour: multiple projects. A/Prof. Barbara Masser (co-appointment)
  Product safety: Detection of Ross River virus in Australian blood donations. Prof. Roy Hall
  Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.): disease burden and consequences for blood supply safety. Prof. John Aaskov,  Prof. Roy Hall (UQ), Dr Helle Bielefeldt-Ohman, Dr John Wright, Dr Jasimme Uddin
  Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate. Dr Jospephine Peevite
  Product safety: The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood. A/Prof. Stephen Mahler, Prof. Matthew Cooper, Prof. Paul Young
University of South Australia Product safety: Chikungunya and/or Zika virus emergence and establishment in Australia. A/Prof. Craig Williams
University of Sydney Donor Behaviour: Behavioural economics to understand blood donations. Evarn Ooi co-appointment with Prof. Robert Slonim
  Centre for Values, Ethics and the Law in Medicine: APPRISE partner. Prof. Angus Dawson
  Product development and storage: Development and characterisation of platelet lysate. Dr Zufu Lu
University of Technology Sydney Donor health and wellbeing: biostatistics, several projects. Louise Ryan
Dr Stephen Wright (co-appointment)
  Product development and storage: Characterisation of cryopreserved platelets.
Product development and storage: Cold storage of platelets.
Dr Matthew Padula
Hospitals    
The Alfred Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Dr Elspeth Hutton
Prince Charles Hospital Product safety: Reducing the risk of TRALI and Reducing the risks associated with transfusion.
Product safety: Transfusion associated immunomodulation in a cohort of cardiac patients – translating laboratory findings to a clinical context.
Prof. John Fraser and the Prince Charles Hospital Critical Care Research Group
Dr Rishendran Naidoo and Prof. John Fraser
Canberra Hospital Product safety: Investigating levels of BRMs in donors implicated in clinical cases of TRALI. Prof. Matthew Cook, Dr Zuopeng Wu
Concord Repatriation and General Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing.
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?
Dr Con Yiannikas
Prof. Peter Maitz , Dr Rosalba Cross
Gosford Hospital Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? Dr Duncan Reed
John Hunter Hospital Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? Prof. Zsolt Balogh
Mater Health Services Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis. Dr Glen Gardener
Orange Health Service Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? Dr Doug Lenton, A/Prof. Brian Burns
Royal Adelaide Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Dr Pravin Hissaria and Dr Janakan Ravindran
Royal Melbourne Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. A/Prof. Timothy Day, Prof. Lynettte Kiers
Royal Prince Alfred  Hospital Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis. Clin Prof. Jon Hyett
  Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen.
Product development and storage: Development and characterisation of platelet lysate.
Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing.
Clin Prof. Jon Hyett
Dr Janet McPherson and Dr James Favaloro
Prof. Matthew Kiernan
St George Hospital Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? Dr Mary Langcake
Sydney Eye Hospital Product development and storage: Development and characterisation of platelet lysate. Simon Cooper
Westmead Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing.
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?
Prof. Steve Vucic, Dr Jeremy Hsu, Dr Leonardo Pasalic
Royal North Shore Hospital Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Dr Karl Ng
  Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? Dr Tony Joseph, Dr Mark Gillett, Dr Lesley Survela
  Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? Prof. Chris Ward
  Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. Prof. James Isbister, Dr Jennifer Bowen, Dr Eleni Mayson
Government Health Departments and Agencies    
Clinical Excellence Commission, NSW Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. Dr Amanda Thomson
Hunter New England Health Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? Prod. David Durrheim
NSW Health Protection Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? TBA
National Centre for Immunisation research and surveillance Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? Dr NIck Wood, Dr Helen Quinn, Prof. Peter McIntyre
NSW Office of Kids and Families Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. Associate Professor Michael Nicholl
Pathwest Laboratory medicine Product safety: Detection of Ross River virus in Australian blood donations. Dr David Smith, Dr Glenys Chidlow
  Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? Dr Linda Hueston
Queensland Health Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety?
Product safety: Detection of Ross River virus in Australian blood donations.
Dr Penny Hutchison, Dr Alyssa Pyke, Dr Sonja Hall-Mendelin
OzFoodNet Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? Dr Robyn Leader, Dr Ben Polonghorne
SA Pathology Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? A/Prof. David Roxby
Research Institutes    
ARC Centre of Excellence for Mathematical & Statistical Frontiers (ACEMS) Donor Health and Wellbeing: 45 and Up: Blood Service data linkage project: a world-class donor health data-asset.
Donor Health and Wellbeing: Safety and feasibility of first appointment plasmapheresis donation.
Donor Health and wellbeing: Development of an Australian statistical model to predict haemoglobin deferrals.
Prof. Louise Ryan
The Australian and New Zealand Intensive Care Research Centre Product usage: TRANSFUSE - Standard Issue Transfusion versus fresher red blood cell use in intensive care - a randomised controlled trial. Prof. DJ Cooper
Burnet Institute Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Prof. Mark Hogarth
Brain and Mind Research Institute Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Prof. Matthew Kiernan
Burnet Institute Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Prof. Mark Hogarth
The Kolling Institute, University of Sydney Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. A/Prof. Jane Ford, Prof. Jonathan Morris, Ms Jillian Patterson
Mater Medical Research Institute Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen. Dr Glenn Gardener
National Centre for Immunisation Reserach and Surveillance Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety? Dr Nick Wood, Dr Helen Quinn, Prof. Peter McIntyre
Sax Institute Donor Health and Wellbeing:  45 and up study: Blood Service data linkage project: a world-class donor health data-asset.  
Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead Product safety: APPRISE partner. Prof. Lyn Gilbert
Queensland Institute of Medical Research-Berghofer Medical research institute Product safety: Detection of Ross River virus in Australian blood donations.
Product safety: Exotic mosquito-borne virus threats to Australia (including WNV,
CHIKV, LNV etc.):disease burden and consequences for blood supply safety.
Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis.
Dr Natalie Prow, Prof Andreas Suhrbier, Dr Greg Devine, Dr Louisa Gordon
Industry    
Australian Defence Force Product usage: Clip Trial - Cryopreserved versus Liquid Stored Platelets for surgical bleeding. Prof. Michael Reade
Blood Systems Research Institute Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.):disease burden and consequences for blood supply safety. Prof. Eric Delwart
CSL Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. Dr Souravi Ghosh, Dr Adrian Zuercher and Dr Bradley Sedgmen
Grifols Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? Dr Jerry Holmberg
Macopharma Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components.  
New Health Sciences Inc Product development and storage: Anaerobic Red Cell storage.  
International    
American Red Cross Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? Dr Susan Stramer
Sanquin Donor health and wellbeing: Development of an Australian statistical model to predict haemoglobin deferrals. Dr Mireille Baart
McMaster University, Canada Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components. Nancy Heddle
Dartmouth Hitchcock USA Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. Dr Larry Dumont
Netherlands Military Blood Bank Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. Dr Femke Noorman
Singapore Defence Medical & Environmental Research Institute Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. Dr Jia Lu
Scottish Blood Transfusion Service Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. Dr Juraj Petrik
New Zealand Blood Service Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. Dr Darryl Crimmins
Environmental Protection Authority, New Zealand Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative? Dr Stacy Scott
Alberta Health Service Canada Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative?